Your browser is no longer supported. Please, upgrade your browser.
Settings
NVS Novartis AG daily Stock Chart
NVS [NYSE]
Novartis AG
Index- P/E25.56 EPS (ttm)2.83 Insider Own9.30% Shs Outstand2.61B Perf Week-1.48%
Market Cap188.69B Forward P/E15.08 EPS next Y4.80 Insider Trans0.03% Shs Float2.53B Perf Month1.66%
Income6.81B PEG6.07 EPS next Q1.12 Inst Own10.10% Short Float0.21% Perf Quarter-5.68%
Sales49.63B P/S3.80 EPS this Y-33.30% Inst Trans0.00% Short Ratio1.58 Perf Half Y-11.29%
Book/sh31.52 P/B2.30 EPS next Y1.80% ROA5.10% Target Price91.60 Perf Year-9.04%
Cash/sh- P/C- EPS next 5Y4.21% ROE9.20% 52W Range66.93 - 83.58 Perf YTD-0.60%
Dividend2.72 P/FCF99.89 EPS past 5Y-7.50% ROI7.80% 52W High-13.38% Beta0.74
Dividend %3.76% Quick Ratio0.80 Sales past 5Y-0.50% Gross Margin64.90% 52W Low8.17% ATR0.98
Employees118000 Current Ratio1.10 Sales Q/Q-1.20% Oper. Margin16.80% RSI (14)50.48 Volatility1.29% 0.98%
OptionableYes Debt/Eq0.35 EPS Q/Q9.10% Profit Margin13.70% Rel Volume1.85 Prev Close72.79
ShortableYes LT Debt/Eq0.24 EarningsJan 25 BMO Payout0.00% Avg Volume3.29M Price72.40
Recom2.00 SMA20-0.02% SMA501.74% SMA200-5.72% Volume6,138,900 Change-0.54%
Jan-11-17Downgrade Credit Suisse Outperform → Neutral
Nov-10-16Upgrade Argus Hold → Buy
Oct-10-16Reiterated Chardan Capital Markets Buy $95 → $92
Sep-20-16Initiated Chardan Capital Markets Buy $95
Apr-12-16Downgrade Morgan Stanley Equal-Weight → Underweight
Mar-23-16Downgrade Leerink Partners Outperform → Mkt Perform
Jun-22-15Upgrade Bryan Garnier Neutral → Buy
Nov-16-09Initiated Deutsche Securities Buy
Nov-12-09Initiated Barclays Capital Underweight $48
Sep-30-09Upgrade Citigroup Hold → Buy
Sep-15-09Upgrade Jefferies & Co Hold → Buy
Jul-17-09Upgrade JP Morgan Neutral → Overweight
Mar-17-09Initiated Credit Suisse Neutral
Feb-27-09Reiterated Credit Suisse Neutral $14 → $7
Jan-26-09Initiated Jefferies & Co Hold
Sep-23-08Upgrade Credit Suisse Underperform → Neutral
Aug-06-08Downgrade JP Morgan Overweight → Neutral
Jun-12-08Downgrade HSBC Securities Neutral → Underweight $52 → $49
Jun-04-08Upgrade Cowen & Co Neutral → Outperform
May-09-08Upgrade Bernstein Mkt Perform → Outperform
Jan-16-17 10:37AM  How Is Novartiss Revenue Trending?
10:14AM  These 5 Drug Patents Will Expire in 2017 at Investopedia
09:07AM  How Did Novartis Perform in 3Q16?
08:38AM  5 Trump-Proof Pharma Dividends Up To 5.3% at Forbes
07:37AM  How Does Novartiss Valuation Compare to Peers?
Jan-13-17 06:11PM  Novartis to Conduct Trial on Obese, Type II Diabetes Patients
03:52PM  [$$] Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs at The Wall Street Journal
10:02AM  Why Juno Therapeutics Crashed 57.1% in 2016 and What's Next at Motley Fool
09:55AM  4 Signs Glaxo's Turnaround Is Taking Hold at Motley Fool
07:09AM  Lilly Wins Appeal Against Teva in Alimta Patent Lawsuit
Jan-12-17 04:25PM  3 Surprises From Pfizer at the J. P. Morgan Healthcare Conference at Motley Fool
12:20PM  Drug makers, auto stocks yank European stocks lower for first time in 3 days at MarketWatch
10:37AM  Mylans Specialty Segment: The Effect of Falling EpiPen Sales
Jan-11-17 01:23PM  The 1 Biotech Stock I Want to Own in 2017 at Motley Fool
12:19PM  Ionis Stocks Surge After Novartis Deal (IONS) at Investopedia
12:09PM  European stocks trim gains after Trump comments send drug stocks lower at MarketWatch
09:53AM  Why Novartis Dropped 15.1% in 2016 at Motley Fool
06:40AM  Novartis AG downgraded by Credit Suisse
Jan-10-17 12:59PM  Todd Hagopian's Top Biotech Takeover Targets For 2017 at Forbes
Jan-09-17 07:49PM  Trumponomics Is Finally Reflating Europe And Japan at Forbes
11:23AM  Takeda Pays $5.2 Billion for Leukemia Drug Maker Ariad, Ending Months of Takeout Speculation
09:01AM  Ionis, Novartis Ink Deal to Focus on Cardiovascular Treatments
08:15AM  Blog Coverage Novartis Joins Hands with Ionis Pharma For Cardiovascular Treatment Solutions Accesswire
07:39AM  Teva Falls on Disappointing 2017 Sales & Earnings Guidance
07:36AM  Whats in Incytes Product Portfolio?
Jan-08-17 02:00PM  3 Takeover Candidates in the Drug Space
Jan-06-17 04:42PM  Roche's (RHHBY) Lucentis Gets FDA Nod for Fifth Indication
04:24PM  Ionis Pharma Stock Bounds On $100 Million Novartis Investment
12:16PM  Ionis, Novartis Ink Collaboration Worth Up to $1.6B Plus Royalties
01:32AM  Novartis joins forces with Ionis on cardiovascular treatments
Jan-05-17 11:52AM  Eli Lilly Announces Exec Appointments, Organizational Changes
Jan-04-17 06:20AM  Greek prosecutor raids Novartis Athens offices in bribery probe
06:04AM  Gilead poaches Novartis cancer specialist Riva
Jan-03-17 01:30PM  Biogen boosts price of top MS drugs, analyst says at bizjournals.com
06:35AM  17 Thoughts on Biotech Stocks to Kick Off 2017
Jan-02-17 05:26PM  Barron's Best Income Ideas For 2017
09:06AM  GlaxoSmithKlines Vaccines Business
Dec-30-16 09:27AM  ARIAD Stock Beats Industry in 2016, Iclusig Sales Strong
09:07AM  How GlaxoSmithKlines Pharmaceuticals Segment Has Performed
07:38AM  Exploring GlaxoSmithKlines Business Segments
Dec-29-16 10:36AM  When Will the Biosimilar for Enbrel Be Available?
07:36AM  United Therapeutics Robust Research Pipeline
Dec-28-16 08:35AM  Eight Milestones Of 2016 In The War On Cancer at Forbes
Dec-27-16 06:05PM  International Segment: Key Driver of VRXs Revenue Growth in 2016
Dec-26-16 07:36AM  Financial Metrics of Baxters Acquisition of Claris Injectables
Dec-24-16 08:06AM  The Most Likely Incyte Acquisition Deal for 2017? at Motley Fool
Dec-23-16 05:48AM  Pharma Stock Roundup: J&J Back in Talks with Actelion, Teva Settles Corruption Probe
Dec-22-16 10:51AM  Bad News Bashes Biotech Investors... Again at Motley Fool
08:01AM  Pfizer Ibrance sNDA Accepted by FDA under Priority Review
Dec-21-16 09:25AM  Biotech Stock Roundup: Conatus Soars on Novartis Deal, Early FDA Nod for Clovis Drug
Dec-20-16 05:31PM  Bristol-Myers Squibb Expects Strong Revenue Growth in 2016
03:06PM  3 Dividend Stocks to Put on Your Shopping List at Motley Fool
12:26PM  Novartis reaches agreement to buy Texas-based Encore Vision
12:00PM  Banking Sector Leading Rally in U.S. Markets
10:46AM  General Mills falls on miss, BlackBerry's profit surprise, Facebook faces EU probe over WhatsApp merger
10:37AM  Novartis AG (ADR) (NVS) Agrees To $50 Million Deal With Conatus Pharmaceuticals Inc (CNAT) at Insider Monkey
10:30AM  Conatus Pharma Doubles On Novartis NASH Liver Drug Licensing Deal
09:20AM  7 Good Stocks for Your Retirement Portfolio in 2017 at Kiplinger
08:53AM  Conatus Stock Up on Liver Drug Collaboration with Novartis
08:50AM  Conatus More Than Doubles on Key License Collaboration Agreement
06:02AM  These 5 Health Care Stocks Are Breaking Out This Christmas
Dec-19-16 05:51PM  Fovista Flops: What's Next? at Motley Fool
05:21PM  Conatus shares skyrocket after Novartis license deal at MarketWatch
05:20PM  Novartis (NVS) Gets Positive CHMP Opinion for Key Drugs
04:14PM  Incyte Could Step Onto Auction Block With Strong Jakafi Sales: RBC
07:33AM  Pharma Stock Roundup: Lilly Up on Guidance, Merck Awarded $2.54B in HCV Case
Dec-17-16 09:05AM  Novartis' Big News at ASH? It's Still in the CAR-T Race at Motley Fool
Dec-16-16 06:51PM  [$$] Novartis Buys Dermatology Company Ziarco at The Wall Street Journal
12:01PM  ETFs with exposure to Novartis AG : December 16, 2016
Dec-15-16 03:39PM  Cramer's lightning round: The stock that's 'lightning in a bottle' at CNBC
06:16AM  Pfizer: FDA Approves Eczema Ointment; Xtandi Fails Study
Dec-14-16 08:04AM  Washington Cuts a Check to Spark Healthcare Innovation at Motley Fool
Dec-13-16 02:12PM  How You Can Profit as the Market for COPD Drugs Grows
09:03AM  Ophthotech Hits 52-Week Low on Unfavorable Fovista Data
Dec-12-16 04:18PM  Regeneron Spikes On Blurry-Eye Win Vs. Failed Ophthotech Drug
02:20PM  Ophthotech Plunges After Eye Drug Fails Phase 3 at Investopedia
02:17PM  Keep An Eye On Regeneron at Barrons.com
10:23AM  Ophthotech Plunges on Eye-Drug-Study Failure
09:36AM  Ibrance Is the Only Registered CDK 4/6 Inhibitor for Breast Cancer
09:18AM  Novartis Offers Positive Data on Breast Cancer Drug LEE011
03:57AM  Novartis eye drug franchise hit by failed Fovista studies
02:52AM  Novartis eye drug franchise takes hit with failed Fovista studies
Dec-10-16 03:22PM  Do Hedge Funds Love Toyota Motor Corporation (ADR) (TM)? at Insider Monkey
Dec-09-16 12:08PM  3 Hot and Undervalued Biotechs That Are Immune to Trump's Threats
Dec-08-16 04:04PM  FitBit, Gilead Sciences in Thursdays 52-Week Low Club at 24/7 Wall St.
01:50PM  Novartis Lung Cancer Drug Beats Chemo in Study at Investopedia
Dec-07-16 09:05AM  Teva Copaxone EU Label to Omit Pregnancy Contraindication
09:00AM  Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study
Dec-06-16 04:49PM  Sanofi May Battle Johnson & Johnson For European Biotech Actelion
08:47AM  Novartis' drug tops chemotherapy in untreated lung cancer patients Reuters
08:27AM  Exclusive: Novartis in talks to sell some central nervous system drugs - sources
08:08AM  Novartis' drug tops standard therapy in untreated lung cancer patients Reuters
07:02AM  Has GlaxoSmithKline Finally Turned the Corner? at Motley Fool
Dec-05-16 05:54PM  Here is What Hedge Funds Think About Chevron Corporation (CVX) at Insider Monkey
04:11PM  What Smart Money Has To Say About Novartis AG (ADR) (NVS) at Insider Monkey
01:07PM  Novartis, Kite Race for Next-Gen Cancer Drug (NVS, KITE) at Investopedia
01:00PM  Here are 4 Mass. biotechs making noise at the ASH conference so far at bizjournals.com
07:15AM  Patient Deaths, Safety Concerns Cause Juno's CAR-T Pipeline to Skid Out
Dec-04-16 07:52AM  Novartis CEO plays down prospects for Actelion bid: Blick Reuters
07:44AM  Novartis CEO plays down prospects for Actelion bid - Blick Reuters
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. It operates through three segments: Pharmaceuticals, Alcon, and Sandoz. The Pharmaceuticals segment offers patented prescription medicines for oncology, neuroscience, retina, immunology and dermatology, respiratory, cardio-metabolic, established medicines, and cell and gene therapies. The Alcon segment provides eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye, and over-the-counter medicines for the eye; and contact lenses and lens care products. The Sandoz segment offers generic prescription medicines that include active ingredients and finished dosage forms of pharmaceuticals for dermatology, respiratory and ophthalmic, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products; and cytotoxic products for the hospital markets, as well as biotechnology manufacturing services to other companies. The company has collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology; and with Caribou Biosciences for the development of drug discovery tools. It also has a strategic collaboration with Cerulean Pharma to develop nanoparticle-drug conjugates for various cancer tumor targets; a collaboration agreement with Perlara PBC to identify definitive therapeutics for lysosomal storage disorders; and a R&D collaboration with Polyphor Ltd. for the nomination of pre-clinical development drug candidates. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures Ltd10% OwnerOct 31Buy13.0084,6151,099,9952,545,652Oct 31 04:50 PM
Novartis Bioventures Ltd10% OwnerOct 31Sale13.003394,40762,575Oct 31 04:50 PM
Novartis Institutes for BioMed10% OwnerMay 11Buy18.00277,7774,999,9865,573,658May 11 06:57 PM
Novartis Bioventures Ltd10% OwnerApr 12Buy10.00300,0003,000,0002,310,924Apr 12 05:09 PM
Novartis Bioventures Ltd10% OwnerFeb 17Buy8.00375,0003,000,0001,873,791Feb 17 06:47 PM